What is the golden dose?
The Mounjaro KwikPen is a pre-filled injection pen designed to deliver four weekly doses. Each dose consists of 0.6 ml of tirzepatide fluid. After the fourth injection, a small amount of fluid usually remains visible in the pen. This remnant is not a bonus dose. It is a deliberate overfill included in the design by the manufacturer, Eli Lilly. This overfill serves two technical purposes: priming (venting the needle) before each injection and ensuring that each of the four prescribed doses is delivered completely and accurately.
The remaining fluid is therefore a technical necessity, not 'extra' medication intended for use.
Why do people try to get the golden dose out?
The idea that usable medication remains in a pen that would otherwise be discarded appeals to people. The temptation to 'waste nothing' is understandable, given the cost of the pen.
Methods can be found on social media where users try to collect the remaining fluid with a separate needle or syringe. This trend spread quickly, partly due to the high awareness of GLP-1 drugs and discussions about availability and price.
What do healthcare professionals say about the golden dose?
Doctors, pharmacists, and the manufacturer themselves are unanimous in their stance: the golden dose is not safe to use. The primary reasons are:
Unknown quantity.
Because an unknown amount of fluid is lost during each flow check, the remaining quantity after four doses is never equal. It is therefore impossible to know how much tirzepatide is still in the pen.
Risk of under- or overdose.
A dose that is too low can reduce the effectiveness of the drug; a dose that is too high can worsen side effects such as nausea, vomiting, and diarrhea.
Loss of sterility
The pen is designed for exactly four doses over four weeks and must then be discarded, even if fluid is still visible. The risk is not in the shelf life of the pen itself, which is officially still valid for 30 days after first use, but in the use of an external needle or syringe to draw out the remainder. This introduces bacteria that are excluded during normal use of the pen.
No clinical substantiation
The use of the remaining fluid has never been tested or approved. The clinical results of Mounjaro are based on consistent, prescribed dosing. An extra, unmeasured dose falls completely outside this substantiation.
Eli Lilly explicitly emphasizes that the KwikPen must be discarded after the fourth injection, even if fluid is still visible.
News: the new pen makes it impossible
Eli Lilly has announced that the Mounjaro KwikPen will be adapted. A redesigned version will be rolled out starting in April 2026. The technical difference: the pen will have a longer internal plunger component, causing the plunger to travel further through the cartridge with each injection. After the fourth dose, it will be visibly at the end, a clear signal that the pen is ready for disposal. This will result in hardly any remaining fluid being visible, thereby practically eliminating the golden dose.
This change concerns only the technical design of the pen. The medication itself, the dosage, and the injection technique remain completely unchanged. During the transition period, users may receive both the old and new pens, depending on pharmacy stock.
Do you have questions about your treatment or dosage? Always discuss this with your doctor or coach.
